Effective vaccination against european strains of porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
AssigneeZoetis Services LLC
InventorsJay Gregory Calvert, Monica Balasch, Maria Fort, Douglas S. Pearce, Marcia L. Keith
Life of this patent
Estimating the term…
Abstract
The present invention provides modified live European PRRS viruses (whether or not recombinant) that have been at all times cultured, maintained, and/or attenuated on non-simian cells, typically porcine cells, wherein such cells express a porcine CD163 receptor, and whereinby vaccines prepared from such viruses are safe and efficacious, and permit the pre-weaning single dose vaccination of swine, typically as early as Day 1 of life.
Claims7
A vaccine for protecting a porcine animal against infection by a PRRS virus, which vaccine comprises:
- (a) a European PRRS virus encoded by the polynucleotide molecule of SEQ ID NO:
- 5 or any polynucleotide which hybridizes thereto under highly stringent conditions, hybridization to filter bound DNA in 0.5 M NaHPO4, 7% SDS, 1 mM EDTA at 65 degrees C., and washing in 0.1×SSC/0.1% SDS at 68 degrees C.;
- (b) said encoding polynucleotide molecule;
- (c) said polynucleotide molecule in the form of a plasmid;
- or (d) a viral vector comprising said polynucleotide molecule;
- in an amount effective to produce immunoprotection against infection, and a carrier suitable for veterinary use, and wherein said vaccine provides early and safe vaccination as early as when the piglet is one day old or less, and wherein said vaccine provides a duration of immunity for up to 6 months.
A method for vaccinating a porcine animal against infection by a European PRRS virus, comprising administering said vaccine between about 12 hours after birth and 3 weeks of age, prior to weaning of said animal, wherein said vaccine comprises
- (a) an isolated polynucleotide molecule comprising a DNA sequence encoding an infectious RNA molecule encoding a European PRRS virus,
- (b) an infectious RNA molecule encoding a European PRRS virus;
- (c) said polynucleotide molecule (a) in the form of a plasmid,
- (d) a viral vector comprising an infectious RNA molecule (b), or
- (e) a European PRRS virus, and wherein
- said vaccine virus was adapted to grow in porcine cells, or non-porcine mammalian cells that express a porcine CD163 receptor, prior to administration of said vaccine virus to porcine animal.
Dependencies are inferred from the claim text.